Influence of Serum β-Cryptoxanthin on Lung Cancer Mortality: An 18-Year Follow-up Cohort Study

2018 ◽  
Vol 118 (9) ◽  
pp. A50
Author(s):  
P. Shankar ◽  
E. Afriyie-Gyawu
2009 ◽  
Vol 124 (8) ◽  
pp. 1900-1906 ◽  
Author(s):  
Angela Neumeyer-Gromen ◽  
Oliver Razum ◽  
Norbert Kersten ◽  
Andreas Seidler ◽  
Hajo Zeeb

2021 ◽  
pp. 2101399
Author(s):  
Guowei Li ◽  
Xuhui Zhang ◽  
Yingxin Liu ◽  
Junguo Zhang ◽  
Likang Li ◽  
...  

BackgroundResearch on glucosamine shows anti-inflammatory and anti-cancer benefits with a minimal adverse effects. We aimed to explore the relationship between use of glucosamine and risk of lung cancer and lung cancer mortality based on data from the large-scale nationwide prospective UK Biobank cohort study.MethodsParticipants were enrolled between the year 2006 and 2010 and followed up to 2020. Cox proportion hazards model were used to assess the relationship between glucosamine use and risk of lung cancer and lung cancer mortality. Subgroup analyses and sensitivity analyses were performed to explore the potential effect modifications and the robustness of main findings.ResultsA total of 439,393 participants (mean age: 56 years; 53% females) with a mean follow-up of 11 years were included for analyses. There were 82,603 (18.80%) participants reporting regular use of glucosamine at baseline. During follow-up, there were 1,971 (0.45%) lung cancer events documented. Glucosamine use was significantly associated with a decreased risk of lung cancer (hazard ratio=0.84, 95% CI: 0.75–0.92, p<0.001) and lung cancer mortality (hazard ratio=0.88, 95% CI: 0.81–0.96, p=0.002) in fully-adjusted models. A stronger association between glucosamine use and decreased lung cancer risk was observed in participants with a family history of lung cancer when compared to those without a family history.ConclusionRegular use of glucosamine was significantly related with decreased risk of lung cancer and lung cancer mortality, based on data from this nationwide prospective cohort study.


2006 ◽  
Vol 48 (11) ◽  
pp. 1166-1172 ◽  
Author(s):  
Djamila Meguellati-Hakkas ◽  
Diane Cyr ◽  
Isabelle St??cker ◽  
Jo??lle F??votte ◽  
Corinne Pilorget ◽  
...  

2019 ◽  
Vol 145 (12) ◽  
pp. 3267-3275 ◽  
Author(s):  
Jihoon Kang ◽  
Yoosoo Chang ◽  
Jiin Ahn ◽  
Sukjoong Oh ◽  
Dong‐Hoe Koo ◽  
...  

2013 ◽  
Vol 28 (2) ◽  
pp. 159-168 ◽  
Author(s):  
Matthias Möhner ◽  
Norbert Kersten ◽  
Johannes Gellissen

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1502-1502
Author(s):  
Niloofar Taghizadeh ◽  
Judith M. Vonk ◽  
H. Marike Boezen

1502 Background: There are indications of an association between Body Mass Index (BMI) and risk of different cancer types. There is dispute whether this association differs between males and females. Methods: We studied the association of BMI at the first survey with risk of mortality from the most common types of cancer (lung, colorectal, breast and prostate cancer) in a large general population-based cohort study (Vlagtwedde-Vlaardingen, 1965-1990) with follow-up on mortality status until 2009. Additionally, we assessed this association based on tertiles of the annual change in BMI (defined as the difference between BMI at last survey and first survey divided by the time between last and first survey). We used 3 categories of BMI (< 25 kg/m2, 25-30 kg/m2, and ≥ 30 kg/m2) and changes in BMI (< 0.02 kg/m2/yr, 0.02-0.2 kg/m2/yr, and > 0.2 kg/m2/yr) in the analyses. The multivariate Cox regression model was adjusted for age, smoking, gender. Analyses were additionally stratified by gender and smoking. Results: Among all 8645 subjects, 1194 died due to cancer (lung cancer: 275; colorectal cancer: 134; breast cancer: 117; prostate cancer: 83). Mortality from all types of cancer was significantly increased in subjects with BMI > 30 kg/m2 (HR (95 % CI)) = 1.22 (1.00-1.48)), especially in females (1.38 (1.06-1.81)) and in never smokers (1.39 (1.02-1.90)). Prostate cancer mortality was significantly increased in males with BMI 25-30 kg/m2 (2.04 (1.90-3.83)) and > 30 kg/m2 (2.61 (1.02-6.67)). This association between prostate cancer mortality and BMI was higher in smokers. Lung cancer mortality risk was decreased in subjects with BMI 25-30 kg/m2 (0.71 (0.54-0.93)) and > 30 kg/m2 (0.82 (0.50-1.32)), especially in males, in smokers, and in smoking males. There were no significant associations between BMI and colorectal or breast cancer mortality nor between change in BMI and mortality from all analyzed types of cancer. Conclusions: We show that an increase in BMI is associated with an increased risk of mortality from all types of cancer in females and with an increased mortality risk from prostate cancer in males but with a decreased lung cancer mortality risk, especially in males. More research is needed into the biological mechanisms that link BMI to cancer.


Sign in / Sign up

Export Citation Format

Share Document